A recent analysis reveals that the incidence rates of soft tissue sarcomas - cancers in muscle, fat, blood vessels, nerves, and tendons - are lower in young U.S. active-duty military servicemen ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

Here are the top 5 soft tissue sarcoma articles of 2025: ...

A recent analysis reveals that the incidence rates of soft tissue sarcomas—cancers in muscle, fat, blood vessels, nerves, and tendons—are lower in young U.S. active-duty military servicemen compared ...

Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or ...

This article first appeared with Targeted Oncology™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma PURPOSE: To evaluate the efficacy, toxicity, and optimal dose rate of gemcitabine in adult patients ...